PKM and small cell lung carcinoma: The current study also demonstrated that LS-SCLC patients with high expression of ERCC1 and PKM2 had shorter median PFS (p=0.028 and p=0.046, respectively) and OS (p=0.014 and p=0.026, respectively), while patients with low levels of TOPOI presented longer PFS (p=0.008) but not OS (p=0.41) compared with those with high mRNA expression.